Neue Aspekte in der Therapie von Schilddrüsenkarzinomen
Standard
Neue Aspekte in der Therapie von Schilddrüsenkarzinomen : Highlights des ASCO-Kongresses 2015. / Lörincz, B B; Topp, S; Knecht, R.
in: HNO, Jahrgang 63, Nr. 9, 09.2015, S. 625-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Konferenzaufsatz in Fachzeitschrift › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neue Aspekte in der Therapie von Schilddrüsenkarzinomen
T2 - Highlights des ASCO-Kongresses 2015
AU - Lörincz, B B
AU - Topp, S
AU - Knecht, R
PY - 2015/9
Y1 - 2015/9
N2 - At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.
AB - At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.
U2 - 10.1007/s00106-015-0052-3
DO - 10.1007/s00106-015-0052-3
M3 - Konferenzaufsatz in Fachzeitschrift
C2 - 26319428
VL - 63
SP - 625
EP - 628
JO - HNO
JF - HNO
SN - 0017-6192
IS - 9
ER -